Literature DB >> 20698800

Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.

Elena Garcia-Martin1, Miriam Idoipe, Laura Maria Gil, Victoria Pueyo, Jorge Alfaro, Luis E Pablo, Maria Luisa Zubiri, Javier Fernandez.   

Abstract

PURPOSE: To assess the efficacy and safety of nonsurgical treatment with imiquimod (IMQ) 5% cream in patients with periocular nodular basal cell carcinoma (BCC).
METHODS: Fifteen patients with clinical and histopathological diagnosis of nodular BCC on the eyelid were treated with IMQ 5% cream once daily, 5 days/week for 6 weeks. Three patients had tumor persistence after photodynamic therapy and 1 patient had failed cryotherapy.
RESULTS: All tumors showed histopathological remission within 3 months of starting IMQ, and sustained clinical remission was documented in each patient after 24-28 months' follow-up. Treatment tolerability was bad in 7 patients with local effects being most problematic, but all symptoms disappeared when treatment ended.
CONCLUSIONS: IMQ therapy is effective for treating periocular BCCs with a cure rate similar to that of surgery. Aesthetic results were rated as excellent. IMQ is a useful alternative to surgery in patients with periocular BCCs when other therapies have failed or are not possible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20698800     DOI: 10.1089/jop.2010.0030

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

Review 1.  Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies.

Authors:  Julien Lanoue; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-05-01

2.  Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation.

Authors:  Martina C Herwig-Carl; Karin U Loeffler
Journal:  Ocul Oncol Pathol       Date:  2019-08-28

3.  Treatment of facial Basal cell carcinoma: a review.

Authors:  Vanessa Smith; Shernaz Walton
Journal:  J Skin Cancer       Date:  2011-04-27

4.  Recent trends in ocular oncology.

Authors:  Swathi Kaliki; Carol L Shields
Journal:  Oman J Ophthalmol       Date:  2011-09

5.  Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial.

Authors:  Erick Marcet Santiago de Macedo; Rachel Camargo Carneiro; Patricia Picciarelli de Lima; Breno Gonçalves Silva; Suzana Matayoshi
Journal:  BMC Ophthalmol       Date:  2015-04-03       Impact factor: 2.209

6.  Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice.

Authors:  Shuangshuang Zhang; Xiangdong Liu; Lihong Mei; Hongfeng Wang; Fang Fang
Journal:  BMC Complement Altern Med       Date:  2016-08-31       Impact factor: 3.659

Review 7.  Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

Authors:  Yingyun Shi; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2017-05-08       Impact factor: 4.147

8.  Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area.

Authors:  Gamze Ozturk Karabulut; Pelin Kaynak; Can Ozturker; Korhan Fazil; Osman Bulut Ocak; Muhittin Taskapılı
Journal:  Indian J Ophthalmol       Date:  2017-01       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.